The high affinity of brodalumab to human IL-17RA blocks the biological activities of the pro-inflammatory cytokines IL-17A, IL-17C, IL-17E, IL-17F, and IL17A/F heterodimer, resulting in inhibition of the inflammation and clinical symptoms associated with psoriasis. This evidence concerns the gene IL17C and psoriasis.